TAThomas Anthony Anderson

Thomas Anthony Anderson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Anthony Anderson has a total of 99 co-authors. Here are the top co-authors by number of shared publications:

  • Elizabeth De Souza

    Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California

    10 shared publications
  • David Yeomans

    Department of Anesthesiology, Perioperative and Pain Medicine, Stanford Medicine, Stanford, California, USA

    6 shared publications
  • Cholawat Pacharinsak

    Stanford University School of Medicine Department of Comparative Medicine Stanford, CA

    5 shared publications
  • Micaela Quinn Dugan

    University of Michigan Medical School, Ann Arbor

    5 shared publications
  • Ellen Wang

    Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA

    4 shared publications
  • Julia M. Rosenbloom

    Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts

    4 shared publications

Latest Publications

  • Noninvasive Diagnostic Ultrasound-Guided Focused Ultrasound-Induced Peripheral Nerve Blockade Attenuates Pain Behaviors in a Model of Chronic Inflammatory Pain

    by Namrata Sangwan, Lidia Mergelian, Michael Klukinov, Morteza Mohammadjavadi, Cholawat Pacharinsak, Kim Butts Pauly, David C Yeomans, Thomas A Anderson

  • Open Access

    Image-guided focused ultrasound for non-invasive modulation of superficial and deep tissues

    by Namrata Sangwan, N. Chris Chaggares, Zahra Torbatian, Thomas Anthony Anderson

  • Exploratory Optimization of Focused Ultrasound Parameters for Selective Peripheral Nerve Fiber Inhibition

    by Namrata Sangwan, Lidia Mergelian, Michael Klukinov, Morteza Mohammadjavadi, Riya Navani, Cholawat Pacharinsak, Kim Butts Pauly, David C. Yeomans, Thomas A. Anderson

    Was not provided for this article.

  • Off Label But on Target: Sevoflurane as a Topical Analgesic

    by Thomas A. Anderson, Andrew Dinh

    Was not provided for this article.

  • Comorbidities Associated With Chronic Pain Among Adolescents

    by Michael R. King, Shizhe Li, Elizabeth De Souza, Andrew Dinh, Cornelius B. Groenewald, T. Anthony Anderson

  • Open Access

    Noninvasive Diagnostic Ultrasound-Guided Focused Ultrasound Enables Selective, Reversible Inhibition of Peripheral Nociceptive Fibers and Prevents Acute Pain

    by Namrata Sangwan, Lidia Mergelian, Michael Klukinov, Morteza Mohammadjavadi, Riya Navani, Cholawat Pacharinsak, Kim Butts Pauly, Jose G. Vilches-Moure, David C. Yeomans, Thomas A. Anderson

    Background: Acute postoperative pain remains a major clinical therapeutic challenge. Current peripheral nerve blockade (PNB) techniques are effective for some patients but are limited by invasiveness, short duration, reliance on highly trained providers, and off-target motor and sensory effects. Focused ultrasound (FUS) is a novel neuromodulatory technology with the potential to achieve noninvasive, selective, reversible, and prolonged inhibition of peripheral nociceptive fibers to prevent and treat acute pain. We hypothesized that noninvasive transcutaneous targeting of the rat sciatic nerve using co-aligned diagnostic ultrasound (dUS) and FUS transducers could produce selective and reversible inhibition of nociceptive pain behaviors while preserving motor and non-nociceptive sensory functions. Methods: In an in vivo rat hindpaw incisional (HPI) pain model, using a novel, transcutaneous dUS-guided FUS system, the sciatic nerve was located with dUS, and FUS energy was applied to it just prior to hindpaw incision. FUS parameters were iteratively adjusted to achieve reversible, selective inhibition of nociceptive behaviors without changing motor and non-pain sensory behaviors. Animals were randomized into six groups: No Intervention (Control), HPI Only (Disease Control), Sham FUS, FUS Only, FUS+HPI (Intervention), and LA+HPI (Positive Control). Primary outcomes were changes in nociceptive sensory functions, assessed by thermal and mechanical sensitivity. Secondary outcomes were changes in non-nociceptive sensory and motor functions, assessed by hindpaw flexion and extension reflexes. Results: Compared with the HPI Only group, the FUS+HPI group demonstrated (1) significant attenuation of hindpaw thermal hypersensitivity from day 0 - week 5.0 and week 8.0 - 16.0 (p < 0.05–0.001); (2) significant attenuation of mechanical hypersensitivity from day 0 until week 4.0 (p < 0.05–0.001); (3) no significant attenuation of flexion; and (4) no significant attenuation of extension. Conclusions: Transcutaneous dUS-guided FUS enables selective, reversible inhibition of Aδ and C nociceptive fiber mediated behaviors while sparing Aα motor and Aβ sensory behaviors. FUS-induced PNB prevented both acute and persistent pain behaviors. These findings support FUS as a promising noninvasive peripheral nerve blockade strategy for acute pain management.

  • Effects of peripheral nerve block adjuvants with and without local anesthetic on ex vivo rodent nerve A-alpha/beta, A-delta, and C fiber activity

    by Micaela Quinn Dugan, Mary Dubus, Alyssa Mae Flippen, Mark Rainier Catapusan, Zara Thomas, Namrata Sangwan, M Klukinov, Cholawat Pacharinsak, David Yeomans, Thomas Anthony Anderson

    Introduction: Preclinical and clinical studies have shown enhanced analgesia when some adjuvant medications are combined with local anesthetics during peripheral nerve (PN) blockade. However, the effects of many adjuvants on individual PN fibers, that is, A-alpha/beta, A-delta, and C, remain poorly characterized. Methods: Using ex vivo rat sciatic nerve electrophysiology, changes in action potential amplitude (AMP) and area under the curve (AUC) for A-alpha/beta, A-delta, and C fibers were used to determine the half-maximal effective concentrations (EC50) for four adjuvants (dexmedetomidine, magnesium, epinephrine, ketorolac) with and without bupivacaine. At a clinically relevant “high” concentration, each adjuvant’s effects on AMP, AUC, and latency to 100% peak AMP were evaluated with and without bupivacaine, then statistically compared with control (no drug) and bupivacaine-alone conditions. Results: EC50s for the four adjuvants were determined for some fibers: dexmedetomidine (A-alpha/beta, A-delta, C fibers), magnesium (A-delta fibers), epinephrine (C fibers), and ketorolac (A-alpha/beta and A-delta fibers). At the high concentrations, adjuvants alone produced few significant differences when compared with control, and adjuvants with bupivacaine produced few significant differences when compared with bupivacaine alone. Discussion: Using ex vivo electrophysiology, we identified EC50s of dexmedetomidine, magnesium, epinephrine, and ketorolac for A-alpha/beta, A-delta, and/or C fiber AMP, demonstrating that these adjuvants have direct effects on PN fibers. Future investigations may benefit by testing different concentrations of adjuvants and bupivacaine in an in vivo model incorporating a broader range of time points.


  • Focused Ultrasound‐Induced Peripheral Nerve Blockade: Duration of Changes to Thermal Withdrawal Latency and Nerve Structure After Focused Ultrasound Application to the Sciatic Nerve in a Rat Model of Acute Pain

    by Gwen Gao, Zara Thomas, Husniye Kantarci, Cholawat Pacharinsak, J. Bradley Zuchero, Kim Butts Pauly, David C. Yeomans, Thomas A. Anderson

    Focused ultrasound (FUS) holds potential to inhibit peripheral nerves to manage pain. We previously found FUS parameters resulting in changes to nerve structure and reversible increased mechanical withdrawal threshold as well as reversible inhibition of motor and non‐pain sensory fibers. However, as behaviors were only followed for 4 weeks and structure for 2 weeks, the duration of increased thermal withdrawal latency and changes to nerve structure were undetermined. We investigated the duration of increased thermal withdrawal latency and nerve structure alterations after FUS application in an acute pain model. FUS was applied directly to the rat sciatic nerve prior to hindpaw (HP) incision; animal behaviors (thermal and mechanical nociceptive thresholds, HP extension and flexion) were assessed for 12 weeks and nerve structure was assessed for 28 weeks. The primary outcome was the change in HP thermal withdrawal latency. Secondary outcomes were the changes to sciatic nerve structure and HP mechanical withdrawal threshold, extension, and flexion. Compared with controls, after FUS application, animals had increased thermal nociceptive thresholds until week 9, increased mechanical nociceptive thresholds until week 2, decreased HP motor response until week 3.5, and decreased HP plantar sensation until week 4. Nerve ultrastructure changes may have persisted until week 24. In this new longer‐term follow‐up study, after invasive FUS application to the sciatic nerve in a rodent model of acute incisional pain, we determined the duration of changes to thermal hyperalgesia, mechanical hyperalgesia, motor, and non‐pain sensory responses, and changes to nerve structure.


  • Whole Nerve Electrophysiology and Analyses of A‐alpha/beta, A‐delta, and C Fiber Action Potentials

    by Alyssa Flippen, Maggie Dubus, Micaela Dugan, Mark Rainier Macaligiw Catapusan, Namrata Sangwan, Michael Klukinov, Cholawat Pacharinsak, David Yeomans, Thomas Anderson

    Ex vivo whole peripheral nerve electrophysiology provides a powerful tool for evaluating the effects of current and potential clinical treatments on nerve impulse transmission. It allows quantitative assessment of nerve conduction through compound action potential (AP) recordings, which can be correlated with sensory and motor changes. However, existing literature lacks a comprehensive methodology for isolating and analyzing APs from individual nerve fiber subtypes (e.g., A‐alpha/beta, A‐delta, and C fibers). This article details the optimal setup conditions and nerve stimulator parameters required to capture APs from specific nerve fibers reliably and provides a detailed and systematic approach for their analysis. © 2025 Wiley Periodicals LLC.Basic Protocol 1: Setup conditions for obtaining individual nerve fiber action potentialsBasic Protocol 2: Nerve handling and parameters for optimal nerve healthBasic Protocol 3: Nerve stimulation to obtain nerve fiber action potentialsSupport Protocol 1: Parameters for A‐alpha/beta fiber stimulation and recordingSupport Protocol 2: Parameters for A‐delta and C fiber stimulation and recordingBasic Protocol 4: Quantitative analysis of nerve fiber action potentialsSupport Protocol 3: A‐alpha/beta fiber analysisSupport Protocol 4: A‐delta fiber analysisSupport Protocol 5: C fiber analysis